Runfeng Co., Ltd. (301035): Model C continues to advance, currency exchange losses affect the performance in 2024.

Event: The company released the 2024 annual report, achieving revenue of 13.296 billion yuan, a year-on-year increase of 15.77%; net income attributable to shareholders of the listed company was 0.45 billion yuan, a year-on-year decrease of 41.63%. According to 2.81.

TianfengMay 13 07:32

Runfeng Co., Ltd.: Announcement on 2024 Annual Report and 2025 First Quarter Report Instructions (English version)

SZSIMay 8 16:30 · Announcements

Runfeng Co., Ltd. (301035.SZ): A total of 0.89% of shares have been repurchased.

Gelonghui, May 7th丨Runfeng Co., Ltd. (301035.SZ) announced that as of April 30, 2025, the company has cumulatively repurchased 2,497,945 shares of the company through a dedicated securities account for share buybacks via centralized bidding, accounting for 0.89% of the current total share capital of the company, with the highest Fill Price at 51.50 yuan per share, the lowest Fill Price at 46.96 yuan per share, and a total transaction amount of 124,815,120.34 yuan (excluding transaction fees). This buyback complies with relevant laws and regulations and the requirements of the company's share repurchase plan.

Gelonghui FinanceMay 7 18:48

Runfeng Co., Ltd. (301035): The performance in Q1 2025 has significantly improved, with the proportion of Business steadily increasing. The mid to long-term value is worth looking forward to.

The company released the 2024 annual report: During the reporting period, it achieved a revenue of 13.296 billion yuan (YoY +16%), net income attributable to the parent company of 0.45 billion yuan (YoY -42%), and non-dedicated net income attributable to the parent company of 0.466 billion yuan (

SWHY ResearchApr 28 16:17

Runfeng Co., Ltd. (301035): Significant impact from foreign exchange in 2024, an exciting start in 2025.

Event description: The company released its 2024 annual report, achieving revenue of 13.3 billion yuan (up 15.8% year-on-year), a Net income attributable of 0.45 billion yuan (down 41.6% year-on-year), and a Net income attributable after deducting non-recurring items of 0.47 billion yuan.

Changjiang SecuritiesApr 27 16:42

Runfeng Co., Ltd.: The business volume of Clomazone accounts for a small proportion of the company's total revenue.

On April 27, Glonghui reported that Runfeng Co., Ltd. stated in a conference call on April 25 that the company's acetamiprid project has completed its expansion in the past year, and the facilities are currently operating at full load and in a stable manner. We understand the market's concern about hot topics, and the current supply shortage of acetamiprid leading to rising market prices will have a certain positive impact on the company's performance; however, the acetamiprid business accounts for a relatively small proportion of the company's overall revenue.

Gelonghui FinanceApr 27 11:33